This study is about testing a medicine called **orforglipron** to see how well it works and how safe it is for people who are overweight or have obesity. Some of these people may also have a condition called **type 2 diabetes**, which means their bodies don't use sugar properly. The study compares orforglipron to a **placebo**, which is a fake treatment with no medicine in it. This helps researchers see if the medicine really works. The study will have two parts: one for people without type 2 diabetes (GZP1) and one for people with type 2 diabetes (GZP2). Before starting, there is a screening process that lasts about 4 weeks. During the study, participants will be tested and checked to make sure they are safe and to see how the medicine is working.

• The study involves a screening period of about 4 weeks before you start taking the medicine.
• Participants will be divided into two groups: one without type 2 diabetes and one with type 2 diabetes.
• There are no specific eligibility criteria for everyone; check specific study parts for details.